Answers are grounded in this paper and cite their sources.
The newly discovered coronavirus SARS-CoV-2 has sparked a worldwide pandemic of COVID-19, which has caused havoc on medical infrastructures, economies, and cultures around the world. Determining the whole scenario is essential since SARS-CoV-2 variants and sub-variants keep appearing after vaccinations and booster doses. The objective of this secondary meta-analysis is to analysis co-infection, secondary infections, and antimicrobial resistance (AMR) in COVID-19 patients. This study used five significant databases to conduct a systematic review and an overlap meta-analysis to evaluate the pooled estimates of co-infections and secondary infections. The summary of the meta-analysis showed an overall co-infection effect of 26.19% (95% confidence intervals CI: 21.39 to 31.01, I2=98.78, n = 14 meta-analysis) among patients with COVID-19. A coinfection effect of 11.13% (95% CI: 9.7 to 12.56, I2=99.14, n = 11 meta-analysis) for bacteria; 9.69% (95% CI: 1.21 to 7.90, I2 =98.33) for fungal and 3.48% (95% CI: 2.15 to 4.81, I2 =95.84) for viruses. A secondary infection effect of 19.03% (95% CI: 9.53 to 28.54, I2 =85.65) was pooled from 2 meta-analyses (Ave: 82 primary studies). This is the first study that compiles the results of all the previous three years meta-analyses into a single source and offers strong proof of co-infections and secondary infections in COVID-19 patients. Early detection of co-infection and AMR is crucial for COVID-19 patients in order to effectively effective treatment.
No takes yet. Share an insight, caveat, or question.
Islam et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: